Matches in DBpedia 2014 for { ?s ?p Malcolm K. Brenner (born August 4, 1951, in the UK) is a British clinical scientist working mostly in the field of gene therapy and immunotherapy applied to malignancy.He was educated at Forest School London and Emmanuel College, Cambridge England. He received his medical degree and subsequent Ph.D. from Cambridge University, England. In the 1980s, he left the UK to work in St. Jude Children's Research Hospital in Memphis. There, he conducted one of the first human gene therapy studies when he transduced bone marrow stem cells with a retroviral vector with the intention of marking them to study their survival and fate. This seminal study demonstrated that engrafted bone marrow stem cells contribute to long-term hematopoiesis and also that contaminating tumor cells in autografts can cause relapse.More recently, his group has become interested in the genetic-modification of T-cells for cancer therapy, cancer vaccines and monoclonal antibodies.He was President of the International Society for Cellular Therapy and President of the American Society of Gene Therapy in 2002–2003. He was appointed Editor in Chief of the journal Molecular Therapy in 2009.Dr. Brenner was appointed Director of the Center for Cell and Gene Therapy by Dr. David Poplack. Dr. Brenner is a full-time faculty member for the Texas Children's Cancer Center at Baylor College of Medicine, Houston, Texas.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Malcolm_Brenner abstract "Malcolm K. Brenner (born August 4, 1951, in the UK) is a British clinical scientist working mostly in the field of gene therapy and immunotherapy applied to malignancy.He was educated at Forest School London and Emmanuel College, Cambridge England. He received his medical degree and subsequent Ph.D. from Cambridge University, England. In the 1980s, he left the UK to work in St. Jude Children's Research Hospital in Memphis. There, he conducted one of the first human gene therapy studies when he transduced bone marrow stem cells with a retroviral vector with the intention of marking them to study their survival and fate. This seminal study demonstrated that engrafted bone marrow stem cells contribute to long-term hematopoiesis and also that contaminating tumor cells in autografts can cause relapse.More recently, his group has become interested in the genetic-modification of T-cells for cancer therapy, cancer vaccines and monoclonal antibodies.He was President of the International Society for Cellular Therapy and President of the American Society of Gene Therapy in 2002–2003. He was appointed Editor in Chief of the journal Molecular Therapy in 2009.Dr. Brenner was appointed Director of the Center for Cell and Gene Therapy by Dr. David Poplack. Dr. Brenner is a full-time faculty member for the Texas Children's Cancer Center at Baylor College of Medicine, Houston, Texas.".